Several other cohorts have demonstrated median survivals ranging between 38 and 67 years in Hb SS patients and 55 and 66 years in Hb SC or Hb Sβ+-thalassemia patients [7,8,9,10,11]. This evidence concerns the gene GSTM1 and thalassemia.